Donation after circulatory death (DCD) liver allografts are increasingly used for transplantation. However, the posttransplantation clinical and quality of life outcomes of DCD recipients are traditionally considered to be inferior compared with donation after brain death (DBD) allograft recipients. Decision making for such marginal organs can be difficult. This study investigated the optimal decision to accept or decline a DCD liver allograft for a patient based on their current health. A Markov decision process model was constructed to predict the 5-year clinical course of patients on the liver transplant waiting list. Clinical outcomes were determined from the UK transplant registry or appropriate literature. Quality-adjusted life years (QALYs) were determined using the condition-specific short form of liver disease quality of life (SF-LDQoL) questionnaire. There were 293/374 (78.3%) eligible patients who completed the SF-LDQoL questionnaire. A total of 73 respondents (24.9%) were before transplant and 220 were after transplant (DBD recipient, 56.3%; DCD recipient, 8.5%; ischemic cholangiopathy patient, 2.4%; retransplant recipient, 7.9%). Predictive modeling indicated that QALYs gained at 5 years were significantly higher in DCD recipients (3.77; 95% confidence interval [CI], 3.44-4.10) compared with those who remained on the waiting list for a DBD transplant with Model for End-Stage Liver Disease (MELD) scores of 15-20 (3.36; 95% CI, 3.28-3.43), or >20 (3.07; 95% CI, 3.00-3.14). There was no significant advantage for individuals with MELD scores <15 (3.55; 95% CI, 3.47-3.63). In conclusion, this model predicts that patients on the UK liver transplant waiting list with MELD scores >15 should receive an offered DCD allograft based on the QALYs gained at 5 years. This analysis only accounts for donor-recipient risk pairings seen in current practice. The optimal decision for patients with MELD scores <15 remains unclear. However, a survival benefit was observed when a DCD organ was accepted.
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First performed in humans in 1963, (1) liver transplantation remains the sole intervention with curative potential for end-stage liver disease. (2) In the United Kingdom, the active waiting list for liver transplantation has more than doubled in the past decade (264 in 2004-2005 to 549 in 2013-2014), (3) highlighting a growing discrepancy between organ demand and availability. In combination with sustained improvements in surgical expertise and posttransplantation care, there has been renewed interest in living donor (4) and splitliver transplantation. (5) Furthermore, expansion of the liver allograft criteria to include previously unconsidered "marginal donors" has involved donor livers from older patients, and from those with underlying pathologies or prolonged ischemic periods. (6) Despite this renewed interest, cadaveric donations comprise over 98% of liver transplantations in the United Kingdom. (7) These are classified as either being from donation after brain death (DBD) or donation after circulatory death (DCD). DCD liver transplantations have become increasingly prevalent in recent years, constituting 17% of all transplantations in [2013] [2014] . (3) However, because of the prolonged warm ischemic period, these allografts are far more susceptible to severe reperfusion injury than DBD livers. (8) As
Abbreviations: BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; DBD, donation after brain death; DCD, donation after circulatory death; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR-QoL, health-related quality of life; IC, ischemic cholangiopathy; ICH, intracerebral hemorrhage; MELD, Model for End-Stage Liver Disease; NHS, National Health Service; QALY, quality-adjusted life year; RT, survival after retransplantation; RTA, renal tubular acidosis; SD, standard deviation; SFLDQoL, short form of liver disease quality of life; T, survival without ischemic cholangiopathy.
a result, DCD recipients often experience inferior outcomes in terms of survival, graft rejection rates, posttransplant complications, (9) (10) (11) (12) and health-related quality of life (HR-QoL). (13, 14) Ischemic cholangiopathy (IC) is a particular concern in DCD recipients (15, 16) and is associated with further increased morbidity, reduced HR-QoL, and often necessitates retransplantation. However, it should be noted that with rigorous organ selection and a sufficiently skilled transplantation team, DCD outcomes can be comparable to DBD patients. (17) (18) (19) Consequently, there is uncertainty with regards to the optimal pathway for those on the liver transplant waiting list. When a liver transplant becomes available, a surgeon can decline a transplant to wait for a potentially "higher quality" DBD liver for their patient, accepting the risk of clinical deterioration and removal from the list or death. (20) Conversely, they may choose to proceed with transplantation, regardless of the organ type, with potentially inferior posttransplantation outcomes. Markov decision process models can be used to model these complex choices, (21) and they might therefore be able to provide crucial clarification in these situations. The aim of this study was to determine the optimal decision for a patient when a DCD liver allograft becomes available based on the current health of the patient.
Patients and Methods

MARKOV MODEL
A Markov decision process model was constructed to reflect the clinical course of patients currently on the UK liver transplant waiting list (Fig. 1) . The model is a necessary simplification of the clinical process. When a DCD liver becomes available (the start of the model), the on-call transplant team together with the patient must decide to either accept or decline this allograft. The latter choice entails the patient remaining on the waiting list until a DBD transplant is available, or until there is significant clinical deterioration.
Patients could exist within 4 pretransplantation health states: 3 based on Model for End-Stage Liver Disease (MELD) score (<15, 15-20, >20), and death (an aggregate measure of death on the waiting list and delisting). Furthermore, there are 4 posttransplantation health states defined as survival without ischemic cholangiopathy (T), survival with IC, survival after retransplantation (RT), or death. Each state has a defined number of actions possible which allows transition from 1 state to another during a cycle, and the probability of this transition is based solely upon their current state.
Each cycle lasted 1 month (30 days), with a limit of 5 years (60 cycles) due to the limited clinical data available beyond this point. Each patient remained within the model until the final cycle (cycle 60) or their death, which acted as an "exit state" (the probability of further transition being 0). The 30-day transition probabilities used in the model are presented in Supporting Table 1 .
The model depends on several fundamental assumptions: there can only be 1 state transition per cycle; the transition probabilities are independent of the underlying cause of end-stage liver disease (ESLD); patients could only receive 1 retransplantation (which could be a DBD organ only); and the type of transplantation would not affect the clinical course of IC.
CLINICAL AND HR-QOL OUTCOMES
Clinical outcomes within the model were primarily derived from data routinely collected for patients who underwent liver transplantation at the 7 UK Liver Transplant Units (extracted from the UK Transplant Registry on August 30, 2012 (22) ); any performed outside the 7 UK Liver Transplant Units; and all procedures including multiorgan, heterotopic, split, or reduced liver transplants. Patients designated as having fulminant liver failure were further excluded as DCD organs are rarely used in this context. All MELD scores referenced are biological MELD scores.
The probabilities of being transplanted or dying on the waiting list (transition probabilities) were determined from US Scientific Registry of Transplant Recipients data, adjusted to the median wait period as determined using UK National Health Service (NHS) Blood and Transplant registry data. (23) Similarly, the clinical outcomes for patients with IC were derived from the literature. (15, 24) IC was defined as strictures, irregularities, or dilatations of the intrahepatic or extrahepatic bile ducts of the liver graft excluding isolated strictures at the bile duct anastomosis, as determined by clinical imaging. (15, 24) HEALTH-RELATED QUALITY OF LIFE Quality-adjusted life years (QALYs) were used to quantify the effectiveness of each decision. The previously validated short form of liver disease quality of life (SFLDQoL) questionnaire (25) was used to assess the HRQoL in pretransplantation and posttransplantation patients. This questionnaire was administered to all patients who attended the Scottish Liver Transplantation Unit for an outpatient clinic or wait-list assessment during the study period (July 16, 2015 to September 3, 2015), after verbal consent was obtained. The electronic patient record was subsequently accessed to obtain additional sociodemographic and clinical information. A priori advice was sought, and formal institutional ethical approval was not required as this study was considered a service evaluation, involving otherwise routinely collected data.
STATISTICAL ANALYSES
Continuous data were summarized as a mean or median and analyzed using parametric or nonparametric tests, as appropriate. Categorical data were crosstabulated and differences in proportions were tested using chi-square or Fisher's exact tests. Survival analyses were performed using Kaplan-Meier estimation and log-rank tests. Where appropriate, multivariate logistic regression analyses were performed for clinical outcomes.
To minimize the impact of missing quality of life data, questionnaires and variables with a substantial number of missing responses were excluded from the analysis and multiple imputation using chained equations (26) was subsequently performed. This method of multiple imputation involves sequential regression of each variable with missing data to provide more credible complete data sets. All questionnaire responses were assigned a value based on the original Likert scale, (25) and all domains were equally weighted before being summated into an overall score. Five complete data sets were imputed, and an overall pooled estimate was generated (in accordance with Rubin's rules (27) ). This was used to assign an average QALY value for each pretransplantation and posttransplantation patient group. "Perfect" health was accorded a value of 1 QALY, whereas death was assigned a value of 0, with intermediate values for all other patient groups.
Probabilistic sensitivity analyses (Monte Carlo simulation, n 5 10,000) and 1-way sensitivity analyses were conducted to account for uncertainties in model parameters, including the length of time on the waiting list. In the base cases of these analyses, the estimated clinical and quality of life outcomes for a patient who received a DCD liver transplant were compared (in turn) with a patient who remained on the waiting list at a MELD score of <15, 15-20, and >20. This allowed simulation of the optimal decision for an individual within each MELD category. These base case values are listed in Table 2 and Supporting Table 1A -C.
All analyses were performed in R, version 2.1 (R Foundation for Statistical Computing, Vienna, Austria), and Markov models were constructed using TreeAge Pro 2011 software (Treeage Software Inc., Williamstown, MA). Two-tailed statistical significance was set at the level P < 0.05.
Results
POSTTRANSPLANTATION CLINICAL OUTCOMES
A total of 488 DCD and 4340 DBD liver transplantations were performed in the United Kingdom between January 1, 2001 and December 31, 2011. The baseline characteristics of donors and recipients were investigated after stratification by type of transplantation (Table  1 ). There were numerous prominent differences between these groups, most notable being significantly lower donor ages (P < 0.001) and MELD scores (P 5 0.03), as well as cold ischemia times (CITs; P < 0.001) and reperfusion times (P < 0.001) in DCD recipients.
Over the 11-year period, there were 4465 primary liver transplantations and 962 (21.5%) posttransplantation deaths, with 158 (16.4%) of these deaths occurring in the first 30 days after transplantation. Those who received a DCD transplantation had significantly lower probability of survival after transplantation over the 11-year period (P 5 0.02). In comparison, there were just 375 retransplantations in the United Kingdom and 129 posttransplantation deaths (34.4%), with 37 of these deaths (28.7%) in the first 30 days.
FIG. 2. Questionnaire completion by patients attending the
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HEALTH-RELATED QUALITY OF LIFE
There were 374 patients eligible for inclusion during the study period (Fig. 2 ). Of these, 306 (81.8%) completed the questionnaire, whereas 46 (12.3%) declined participation, and 22 (5.9%) were not encountered. A further 13 (3.5%) were subsequently excluded due to questionnaire incompleteness; therefore, 293 patients (78.3%) were included in the final analyses. A total of 73 respondents (24.9%) were before transplantation, and 220 were after transplantation-either DBD (56.3%), DCD (8.5%), patients with IC (2.4%), or retransplant (7.9%) recipients. The level of missingness was <5% for all questions used in the multiple imputation model with the exception of questions 2a (20%), 2b (18%), 2c (16%), and 7 (10%). Three questions (9a, 9b, 10) related to sexual function were excluded due to levels of missingness >20%. The average overall score for each patient group was used to attribute QALY values to each ( Table 2 ). The posttransplant group reported a significantly higher overall HR-QoL than the pretransplant groups (mean score difference, 13.7; 95% confidence interval [CI], 9.7-17.6; P < 0.001). There was no significant difference in the QALYs associated with different MELD scores in the pretransplant groups. However, the DBD liver recipients reported a significantly higher overall HR-QoL compared with DCD liver recipients (mean score difference, 5.9; 95% CI, 0.02-11.8; P 5 0.049).
MODEL FINDINGS
The model provided a quantification of the predicted outcome for patients over time for either decision and across different initial MELD scores ( Fig. 3; Table 3 ). Declining an available DCD transplant was associated with substantially higher mortality at the model end point (60 months) in all cases, which increased with higher MELD categories. In contrast, the decision to offer DCD transplantation was associated with the highest 5-year survival without complications (81.6%). However, those patients had a considerably higher predicted probability of IC (5.3%).
The base analyses (Table 4) indicate that DCD transplantation would be associated with the highest QALYs gained at the model end point. Furthermore, there was an inverse relationship between the MELD category and the QALYs gained by remaining on the waiting list for DBD transplantation. Subsequent probabilistic sensitivity analyses indicated that proceeding with DCD transplantation remained the optimal choice (3.77 QALYs; 95% CI, 3.44-4.10) for a patient with a MELD score 15. However, for patients with MELD scores <15, there is no significant difference in the QALYs gained, and so the optimal decision (in terms of quality of life) for these patients remains unclear.
One-way sensitivity analyses were also conducted to assess the validity of this conclusion across the minimum (0.000) to maximum (0.083) QALYs per month range (Fig. 4) . Proceeding with transplantation remained the optimal decision for patients in all MELD categories when the QALYs in pretransplantation patients and posttransplant patients with IC were investigated. As a sensitivity analysis, the predicted number of QALYs gained after DCD transplantation was varied to identify the lower threshold below which there is no difference in outcome between the two decisions: MELD < 15 (0.057 QALYs per month), 15-20 (0.053 QALYs per month), and >20 (0.048 QALYs per month). Therefore, QALYs from DCD transplantation require to be higher than these thresholds for the described differences in outcome to exist.
Discussion
The demand for liver transplantation continues to rise, as does utilization of DCD allografts, (3) and in the United Kingdom the NHS is implementing strategies to further expand the proportion of DCD organs available. (28) Therefore, it is increasingly important to improve the understanding of which patients would gain the most benefit from DCD allografts. This study aimed to determine the optimal decision for a patient when a DCD liver transplant becomes available-for the surgeon to either accept or refuse this allograftbased on the current health of their patient. As such, this represents the first assessment of the comparative effectiveness of liver allograft acceptance strategies for the United Kingdom. In particular, this model adopts a patient-centered perspective, quantified as QALYs gained after 5 years, under the rationale that "the ultimate measure by which to judge the quality of a medical effort is whether it helps patients (and their families) as they see it." (29) This is an important difference from models which assume a health-system perspective, (30, 31) quantifying the decision in terms of the cost-effectiveness to enable policy makers to allocate limited resources most appropriately. (32) It must be noted that cost-effectiveness was not assessed within the current model, and that as DCD allografts are associated with increased morbidity, retransplantation rates, and mortality, (9) (10) (11) (12) these entail substantially higher posttransplantation costs. (33) Although the cost-effectiveness of DCD liver transplantation has not been formally evaluated in the United Kingdom, (34) wait-list strategies involving these organs have been identified as cost-effective in comparison to DBD-only strategies. (30) This can be attributed to reductions in the burden of disease (and associated costs) in end-stage liver disease patients.
This model predicts that patients who receive the DCD transplant have significantly higher 5-year posttransplant survivals, IC rates, and QALYs gained compared with patients with MELD scores >15 where the offered allograft is declined. Therefore, the optimal decision for these patients is for the DCD liver transplant to be accepted when it becomes available. It is important to recognize that this analysis is only valid for the DCD donor-recipient pairings currently seen in actual practice. It says nothing of the outcomes if higher risk donor-recipient pairings are undertaken. Moreover, this choice remains unclear in patients with MELD scores <15 given the absence of a significant QALY difference. This contrasts with a similar Markov model (31) that predicted only patients with MELD scores >20 would gain significant benefit from accepting DCD allografts. One-way sensitivity analysis indicated that these conclusions persist over a range of QALY values for pretransplant patients and posttransplant patients with IC at different MELD score categories (Fig. 4) , and there is evidence to suggest that MELD score correlates poorly with HRQoL measures. (35) In addition, the thresholds observed during sensitivity analysis of the QALYs after DCD transplantation (Fig. 4) lay outside of the 95% CI (Table 2) , and so this further increases confidence in the robustness of the model. Furthermore, the model demonstrated that the decision to accept a DCD organ was associated with the highest 5-year survival without complications at the model end point (Table 3 ; Fig. 3) .
One of the foremost strengths of this study is the use of the UK Transplant Registry to allow calculation and adjustment of clinical outcomes. This large patient database provided high-quality longitudinal clinical data, which allows the model results to be generalized to all UK units. Although there were significant differences observed in the baseline characteristics of the DBD and DCD transplantation groups, this is undoubtedly an artifact of the highly selective criteria for DCD liver transplantation allografts and recipients. (36) Furthermore, because the large sample size provides substantial statistical power, significant differences should be interpreted in the context of clinical importance. These differences were accounted for in the multivariate regression analyses to produce independent predictions of patient survival. However, the database does possess several limitations. First, the data needed for the waiting list and IC patient clinical outcomes were not included, and so these were derived from published literature. (23, 37) These studies were within US populations, and so may not accurately reflect the clinical situation in the United Kingdom.
In 2014, the majority (56%) of liver transplant recipients in the United States had MELD scores of <30. (6) These patients composed just 34% of liver transplant recipients in the 2001-2011 NHS Blood and Transplant registry database (at the time of transplant, based on the biochemical results). On balance, it was concluded that the practical benefits of further nuance within the model outweighed the theoretical concerns of generalizability. Second, the survival curves (Fig. 2) indicate the majority of liver transplant patients survive beyond the 11-year period the database covers. However, as all surviving patients were censored on December 31, 2011, patients varied in posttransplantation follow-up period. As a result of limited longterm data, the model results were based on the first 5 years after transplantation only. Therefore, it is important to recognize that the conclusions of the model could alter if individual patient follow-up was extended.
A further advantage of this study is the incorporation of population-specific quality of life data into the model, in contrast to literature-derived values, (30, 31) or complete omission, (38, 39) as seen in other Markov models of liver transplantation. However, our model assumes that the responses from the Scottish Liver Transplant Unit patients are generalizable to the UK cohort as a whole. This is a reasonable assumption given the demographic makeup of the United Kingdom. Furthermore, it is important to recognize the impact patient experience and non-health-related factors can have on patient-reported outcome measures, (40) and these may differ between the UK units. In addition, an excellent questionnaire response rate (81.8%) was obtained, which compares favorably with other HRQoL studies in these populations. (14, 41, 42) Therefore, volunteer and selection biases were minimized. Nevertheless, because of the limited data collection period, it must be recognized that clinic attendees are more likely to have higher MELD scores, shorter postoperative periods, or higher complication rates and/or severities. Therefore, these factors could have led to an underestimation of the HR-QoL observed in respondents. Alternately, patients with the worst posttransplantation health may have died or been retransplanted, thus these results have inherent positive bias. This would be of greatest concern in the IC group, particularly given the low sample size, and so may explain the high HRQoL observed. Nevertheless, when the QALYs for IC patients were explored, this did not alter the conclusions of the model. We are planning a conditionspecific HR-QoL questionnaire extended into a UKwide longitudinal study of routine clinical practice within the liver transplant units which will confirm or refute the assumptions implicit in this analysis.
There are also several limitations and necessary assumptions implicit within the Markov model that should be considered. First, the model only compares outcomes after DCD and DBD transplantation, and so the conclusions must be interpreted in view of alternative forms of liver transplantation, including split or reduced livers, living liver donation, and multiorgan transplantation. In addition, the clinical and HR-QoL outcomes presented in this article are generalizations. Therefore, it is essential that there is consideration of the specific organ-and patient-related factors (including etiology of liver disease), and the anticipated local waiting time for DBD transplantation in the decision to accept a DCD organ. Furthermore, the MELD score used here does not include exception points used in some organ transplant jurisdictions for patients with hepatocellular carcinoma (HCC). However, because these patients are expected to have a higher mortality risk on the waiting list compared with their biological MELD, (43) the model results could represent a conservative estimate of the benefits of DCD transplantation. Finally, this model assumed that all retransplantations were performed with a DBD organ, and so the conclusions regarding the use of DCD can only be applied to the patient's first transplantation.
Future work will focus on improving the model reliability including the following: obtaining UK-specific clinical data on the waiting list and IC epidemiology; expansion of a condition-specific HR-QoL questionnaire into a UK-wide longitudinal study or routine clinical practice; direct comparison of the outcomes from different primary liver diseases, including the presence of HCC; and extension of the UK Transplant Registry database to allow determination of longerterm patient outcomes. Furthermore, with appropriate input from medical informatics specialists, this model could be developed into an application that medical staff could use to help inform the optimal decision for individual patients at the point of being offered DCD liver transplantation. As the clinical outcomes are derived from routinely available data, these could be regularly updated to reflect changes in clinical practice.
In conclusion, this Markov model predicted that DCD liver transplantation would provide significantly higher QALYs gained by 5 years for average patients on the waiting list with MELD scores >15. Therefore, from a quality of life perspective, an offered DCD liver transplantation should be accepted in this patient cohort. The optimal decision for average patients with MELD scores <15 remains unclear. However, the model also demonstrated a survival benefit in patients when a DCD organ was accepted. Nonetheless, it is essential that there is consideration of the specific organ-and patient-related risk factors (including etiology of liver disease and prior liver transplantation), and the anticipated local waiting time for DBD transplantation in the decision to accept a DCD organ.
